Diaceutics PLC Canaccord Genuity 43rd Annual Growth Conference
August 04 2023 - 1:00AM
RNS Non-Regulatory
TIDMDXRX
Diaceutics PLC
04 August 2023
04 August 2023
Diaceutics PLC
("Diaceutics" or "the Company")
Diaceutics to present at Canaccord Genuity 43rd Annual Growth
Conference in Boston
Diaceutics PLC (AIM: DXRX), a leading technology and solutions
provider to the pharmaceutical industry, today announces that
management will attend and present at the Canaccord Genuity 43(rd)
Annual Growth Conference taking place on August 7-10 in Boston,
MA.
The Conference brings together investors from around the world
with some of the best and most promising growth companies in
Canaccord's core sectors - Technology, Healthcare, Digital &
Tech-Enabled Health, Sustainability, Industrials, and Consumer
& Retail. For more information please click here .
Enquiries:
Diaceutics PLC Tel: +44 (0)28 9040 6500
Peter Keeling, Chief Executive Officer investorrelations@diaceutics.com
Ryan Keeling, Chief Innovation Officer
Nick Roberts, Chief Financial Officer
Stifel Nicolaus Europe Limited (Nomad Tel: +44 (0)20 7710 7600
& Broker)
Ben Maddison
Nick Harland
Kate Hanshaw
Alma PR Tel: +44 (0)20 3405 0205
Caroline Forde diaceutics@almapr.co.uk
Matthew Young
Kinvara Verdon
About Diaceutics
At Diaceutics we believe that every patient should get the
opportunity to receive the right test and the right therapy to
positively impact their disease outcome. We provide the world's
leading pharmaceutical and life science companies with solutions
and technology for the commercialisation of their precision
medicines, enabled by our proprietary DXRX platform.
DXRX is the world's first diagnostic commercialisation platform
for precision medicine, utilising a global network of affiliate
laboratories to deliver multiple pipelines of real-world healthcare
data insights, advisory services and innovative platform enabled
solutions.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRANKNBQQBKDFFK
(END) Dow Jones Newswires
August 04, 2023 02:00 ET (06:00 GMT)
Diaceutics (LSE:DXRX)
Historical Stock Chart
From Apr 2024 to May 2024
Diaceutics (LSE:DXRX)
Historical Stock Chart
From May 2023 to May 2024
